OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Bought by Triodos Investment Management BV

Triodos Investment Management BV grew its position in OrthoPediatrics Corp. (NASDAQ:KIDS) by 29.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 93,000 shares of the company’s stock after acquiring an additional 21,000 shares during the period. Triodos Investment Management BV’s holdings in OrthoPediatrics were worth $2,156,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Quarry LP purchased a new position in shares of OrthoPediatrics in the 3rd quarter valued at about $25,000. R Squared Ltd acquired a new stake in OrthoPediatrics during the fourth quarter worth approximately $48,000. KLP Kapitalforvaltning AS purchased a new stake in shares of OrthoPediatrics during the 4th quarter worth approximately $79,000. BNP Paribas Financial Markets grew its position in shares of OrthoPediatrics by 125.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after buying an additional 1,929 shares during the last quarter. Finally, Quantbot Technologies LP raised its stake in OrthoPediatrics by 42.2% during the 3rd quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock worth $157,000 after acquiring an additional 1,712 shares in the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Price Performance

OrthoPediatrics stock opened at $24.75 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The business has a 50 day simple moving average of $24.80 and a 200-day simple moving average of $25.32. OrthoPediatrics Corp. has a 12 month low of $21.02 and a 12 month high of $35.99. The stock has a market capitalization of $601.10 million, a PE ratio of -20.12 and a beta of 1.22.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. The company had revenue of $52.67 million during the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter last year, the business earned ($0.23) EPS. Equities analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

KIDS has been the topic of a number of research analyst reports. Truist Financial cut their target price on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Needham & Company LLC reiterated a “buy” rating and issued a $42.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, March 5th. Finally, Stifel Nicolaus cut their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th.

Insiders Place Their Bets

In related news, CEO David R. Bailey sold 6,620 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company’s stock, valued at $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the sale, the general counsel now owns 110,767 shares of the company’s stock, valued at approximately $2,753,667.62. This trade represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,732 shares of company stock worth $589,978. Corporate insiders own 31.80% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.